Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2003 Jul 15;373(Pt 2):593–601. doi: 10.1042/BJ20030167

Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.

R De Cristofaro 1, V De Filippis 1
PMCID: PMC1223494  PMID: 12689334

Abstract

Activation of factor VIII (FVIII) by thrombin plays a fundamental role in the amplification of the coagulation cascade and takes place through specific proteolytic cleavages at Arg(372), Arg(740) and Arg(1689). Full FVIII activation requires cleavage at Arg(372), a process involving the alpha-thrombin exosite-II; referred to as heparin-binding site (HBS). The present study was aimed at investigating the effect of glycoprotein Ibalpha (GpIbalpha; 1-282 fragment) binding to thrombin HBS on FVIII activation. Similar experiments were also performed using a synthetic peptide modelled on the 268-282 sequence of GpIbalpha, and sulphated successfully at all tyrosine residues present along its sequence, at positions 276, 278 and 279. Both GpIbalpha 1-282 and the sulphated GpIb 268-282 peptides induced a progressive decrease (up to 70%) in activated FVIII generation, assessed by coagulation and FXa-generation assays. Furthermore, SDS/PAGE and Western-blot experiments showed that the specific appearance of the 44 kDa A2 domain on cleavage of the FVIII Arg(372)-Ser(373) peptide bond was delayed significantly in the presence of either GpIbalpha 1-282 or GpIb 268-282 peptide. Moreover, the effect of the latter on thrombin-mediated hydrolysis of a peptide having the sequence 341-376 of FVIII was investigated using reverse-phase HPLC. The k (cat)/ K (m) values of the FVIII 341-376 peptide hydrolysis by thrombin decreased linearly as a function of the GpIbalpha 268-282 peptide concentration, according to a competitive inhibition effect. Taken together, these experiments suggest that the sulphated 268-282 region of GpIbalpha binds to thrombin HBS, and is responsible for the inhibition of the Arg(372)-Ser(373) bond cleavage and activation of FVIII.

Full Text

The Full Text of this article is available as a PDF (192.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai M., Inaba H., Higuchi M., Antonarakis S. E., Kazazian H. H., Jr, Fujimaki M., Hoyer L. W. Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine). Proc Natl Acad Sci U S A. 1989 Jun;86(11):4277–4281. doi: 10.1073/pnas.86.11.4277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arni R. K., Padmanabhan K., Padmanabhan K. P., Wu T. P., Tulinsky A. Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin. Biochemistry. 1993 May 11;32(18):4727–4737. doi: 10.1021/bi00069a006. [DOI] [PubMed] [Google Scholar]
  3. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992 Apr;1(4):426–471. doi: 10.1002/pro.5560010402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buchanan S. G., Gay N. J. Structural and functional diversity in the leucine-rich repeat family of proteins. Prog Biophys Mol Biol. 1996;65(1-2):1–44. doi: 10.1016/s0079-6107(96)00003-x. [DOI] [PubMed] [Google Scholar]
  5. Curtis J. E., Helgerson S. L., Parker E. T., Lollar P. Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem. 1994 Feb 25;269(8):6246–6251. [PubMed] [Google Scholar]
  6. De Candia E., Hall S. W., Rutella S., Landolfi R., Andrews R. K., De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2000 Nov 17;276(7):4692–4698. doi: 10.1074/jbc.M008160200. [DOI] [PubMed] [Google Scholar]
  7. De Cristofaro R., De Candia E., Landolfi R., Rutella S., Hall S. W. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry. 2001 Nov 6;40(44):13268–13273. doi: 10.1021/bi010491f. [DOI] [PubMed] [Google Scholar]
  8. De Cristofaro R., De Candia E., Rutella S., Weitz J. I. The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. J Biol Chem. 2000 Feb 11;275(6):3887–3895. doi: 10.1074/jbc.275.6.3887. [DOI] [PubMed] [Google Scholar]
  9. Díaz-Ricart M., Estebanell E., Lozano M., Aznar-Salatti J., White J. G., Ordinas A., Escolar G. Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions. Haematologica. 2000 Mar;85(3):280–288. [PubMed] [Google Scholar]
  10. Esmon C. T., Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem. 1996 Jun 7;271(23):13882–13887. doi: 10.1074/jbc.271.23.13882. [DOI] [PubMed] [Google Scholar]
  11. Fredenburgh J. C., Stafford A. R., Weitz J. I. Evidence for allosteric linkage between exosites 1 and 2 of thrombin. J Biol Chem. 1997 Oct 10;272(41):25493–25499. doi: 10.1074/jbc.272.41.25493. [DOI] [PubMed] [Google Scholar]
  12. Fulcher C. A., Roberts J. R., Zimmerman T. S. Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide. Blood. 1983 Apr;61(4):807–811. [PubMed] [Google Scholar]
  13. Gan Z. R., Li Y., Chen Z., Lewis S. D., Shafer J. A. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J Biol Chem. 1994 Jan 14;269(2):1301–1305. [PubMed] [Google Scholar]
  14. Gast A., Tschopp T. B., Baumgartner H. R. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb. 1994 Sep;14(9):1466–1474. doi: 10.1161/01.atv.14.9.1466. [DOI] [PubMed] [Google Scholar]
  15. Gitschier J., Kogan S., Levinson B., Tuddenham E. G. Mutations of factor VIII cleavage sites in hemophilia A. Blood. 1988 Sep;72(3):1022–1028. [PubMed] [Google Scholar]
  16. Heras M., Chesebro J. H., Webster M. W., Mruk J. S., Grill D. E., Penny W. J., Bowie E. J., Badimon L., Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990 Oct;82(4):1476–1484. doi: 10.1161/01.cir.82.4.1476. [DOI] [PubMed] [Google Scholar]
  17. Hill-Eubanks D. C., Parker C. G., Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6508–6512. doi: 10.1073/pnas.86.17.6508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Huizinga Eric G., Tsuji Shizuko, Romijn Roland A. P., Schiphorst Marion E., de Groot Philip G., Sixma Jan J., Gros Piet. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002 Aug 16;297(5584):1176–1179. doi: 10.1126/science.107355. [DOI] [PubMed] [Google Scholar]
  19. Kitagawa K., Aida C., Fujiwara H., Yagami T., Futaki S., Kogire M., Ida J., Inoue K. Facile solid-phase synthesis of sulfated tyrosine-containing peptides: total synthesis of human big gastrin-II and cholecystokinin (CCK)-39. J Org Chem. 2001 Jan 12;66(1):1–10. doi: 10.1021/jo000895y. [DOI] [PubMed] [Google Scholar]
  20. Li C. Q., Vindigni A., Sadler J. E., Wardell M. R. Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin. J Biol Chem. 2000 Oct 9;276(9):6161–6168. doi: 10.1074/jbc.M004164200. [DOI] [PubMed] [Google Scholar]
  21. López J. A., Dong J. F. Structure and function of the glycoprotein Ib-IX-V complex. Curr Opin Hematol. 1997 Sep;4(5):323–329. doi: 10.1097/00062752-199704050-00005. [DOI] [PubMed] [Google Scholar]
  22. Marchese P., Murata M., Mazzucato M., Pradella P., De Marco L., Ware J., Ruggeri Z. M. Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. J Biol Chem. 1995 Apr 21;270(16):9571–9578. doi: 10.1074/jbc.270.16.9571. [DOI] [PubMed] [Google Scholar]
  23. Matsushita T., Meyer D., Sadler J. E. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem. 2000 Apr 14;275(15):11044–11049. doi: 10.1074/jbc.275.15.11044. [DOI] [PubMed] [Google Scholar]
  24. McGhie A. I., McNatt J., Ezov N., Cui K., Mower L. K., Hagay Y., Buja L. M., Garfinkel L. I., Gorecki M., Willerson J. T. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation. 1994 Dec;90(6):2976–2981. doi: 10.1161/01.cir.90.6.2976. [DOI] [PubMed] [Google Scholar]
  25. Michnick D. A., Pittman D. D., Wise R. J., Kaufman R. J. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem. 1994 Aug 5;269(31):20095–20102. [PubMed] [Google Scholar]
  26. Monroe Dougald M., Hoffman Maureane, Roberts Harold R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1381–1389. doi: 10.1161/01.atv.0000031340.68494.34. [DOI] [PubMed] [Google Scholar]
  27. Moroder L., Wilschowitz L., Jaeger E., Knof S., Thamm P., Wünsch E. Synthese von Tyrosin-O-sulfat-haltigen Peptiden. Hoppe Seylers Z Physiol Chem. 1979 Jun;360(6):787–790. [PubMed] [Google Scholar]
  28. Mruk J. S., Webster M. W., Heras M., Reid J. M., Grill D. E., Chesebro J. H. Flavone-8-acetic acid (Flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury In vivo. Circulation. 2000 Jan 25;101(3):324–328. doi: 10.1161/01.cir.101.3.324. [DOI] [PubMed] [Google Scholar]
  29. Myles T., Yun T. H., Hall S. W., Leung L. L. An extensive interaction interface between thrombin and factor V is required for factor V activation. J Biol Chem. 2001 Apr 18;276(27):25143–25149. doi: 10.1074/jbc.M011324200. [DOI] [PubMed] [Google Scholar]
  30. Myles Timothy, Yun Thomas H., Leung Lawrence L. K. Structural requirements for the activation of human factor VIII by thrombin. Blood. 2002 Oct 15;100(8):2820–2826. doi: 10.1182/blood-2002-03-0843. [DOI] [PubMed] [Google Scholar]
  31. Ohyama T., Hori T., Moriike M., Asano T., Hayashi H., Iwade K., Hosoda S. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis. Thromb Haemost. 1998 Feb;79(2):423–430. [PubMed] [Google Scholar]
  32. Patrono C., Coller B., Dalen J. E., FitzGerald G. A., Fuster V., Gent M., Hirsh J., Roth G. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest. 2001 Jan;119(1 Suppl):39S–63S. doi: 10.1378/chest.119.1_suppl.39s. [DOI] [PubMed] [Google Scholar]
  33. Richardson J. L., Kröger B., Hoeffken W., Sadler J. E., Pereira P., Huber R., Bode W., Fuentes-Prior P. Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. EMBO J. 2000 Nov 1;19(21):5650–5660. doi: 10.1093/emboj/19.21.5650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sadler J. Evan. Biomedicine. Contact--how platelets touch von Willebrand factor. Science. 2002 Aug 16;297(5584):1128–1129. doi: 10.1126/science.1075452. [DOI] [PubMed] [Google Scholar]
  35. Saenko E. L., Scandella D., Yakhyaev A. V., Greco N. J. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem. 1998 Oct 23;273(43):27918–27926. doi: 10.1074/jbc.273.43.27918. [DOI] [PubMed] [Google Scholar]
  36. Savage B., Almus-Jacobs F., Ruggeri Z. M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998 Sep 4;94(5):657–666. doi: 10.1016/s0092-8674(00)81607-4. [DOI] [PubMed] [Google Scholar]
  37. Sheehan J. P., Sadler J. E. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5518–5522. doi: 10.1073/pnas.91.12.5518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Soslau G., Class R., Morgan D. A., Foster C., Lord S. T., Marchese P., Ruggeri Z. M. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem. 2001 Mar 30;276(24):21173–21183. doi: 10.1074/jbc.M008249200. [DOI] [PubMed] [Google Scholar]
  39. Tasset D. M., Kubik M. F., Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol. 1997 Oct 10;272(5):688–698. doi: 10.1006/jmbi.1997.1275. [DOI] [PubMed] [Google Scholar]
  40. Uff Sarah, Clemetson Jeannine M., Harrison Tim, Clemetson Kenneth J., Emsley Jonas. Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem. 2002 Jun 26;277(38):35657–35663. doi: 10.1074/jbc.M205271200. [DOI] [PubMed] [Google Scholar]
  41. Vasudevan S., Roberts J. R., McClintock R. A., Dent J. A., Celikel R., Ware J., Varughese K. I., Ruggeri Z. M. Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibalpha. J Biol Chem. 2000 Apr 28;275(17):12763–12768. doi: 10.1074/jbc.275.17.12763. [DOI] [PubMed] [Google Scholar]
  42. Verhamme Ingrid M., Olson Steven T., Tollefsen Douglas M., Bock Paul E. Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. J Biol Chem. 2001 Nov 27;277(9):6788–6798. doi: 10.1074/jbc.M110257200. [DOI] [PubMed] [Google Scholar]
  43. Ward C. M., Andrews R. K., Smith A. I., Berndt M. C. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry. 1996 Apr 16;35(15):4929–4938. doi: 10.1021/bi952456c. [DOI] [PubMed] [Google Scholar]
  44. Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. Thromb Haemost. 1998 Mar;79(3):466–478. [PubMed] [Google Scholar]
  45. Weitz J. I., Hirsh J. New anticoagulant drugs. Chest. 2001 Jan;119(1 Suppl):95S–107S. doi: 10.1378/chest.119.1_suppl.95s. [DOI] [PubMed] [Google Scholar]
  46. Yagami T., Shiwa S., Futaki S., Kitagawa K. Evaluation of the final deprotection system for the solid-phase synthesis of Tyr(SO3H)-containing peptides with 9-fluorenylmethyloxycarbonyl (Fmoc)-strategy and its application to the synthesis of cholecystokinin (CCK)-12. Chem Pharm Bull (Tokyo) 1993 Feb;41(2):376–380. doi: 10.1248/cpb.41.376. [DOI] [PubMed] [Google Scholar]
  47. de Cristofaro R., Rocca B., Bizzi B., Landolfi R. The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin. Biochem J. 1993 Jan 15;289(Pt 2):475–480. doi: 10.1042/bj2890475. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES